Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals.
Lawn SD, Kerkhoff AD, Wood R.
AIDS. 2011 Nov 13;25(17):2190-1. No abstract available.
Related citations
Plasma biomarkers in the prediction and diagnosis of tuberculosis-associated immune reconstitution inflammatory syndrome.
French MA, Oliver BG, Elliott JH, Price P.
AIDS. 2011 Aug 24;25(13):1676-7. No abstract available.
Error occurred: cannot get document summary
Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa.
Lawn SD, Harries AD.
AIDS. 2011 Jul 31;25(12):1554-5; author reply 1556. No abstract available.
Bevacizumab reverts serous retinal detachment caused by tuberculosis-associated immune reconstitution inflammatory syndrome.
Ruiz-Cruz M, Espinosa E, Romero K, Reyes-Terán G.
AIDS. 2011 Jun 1;25(9):1241-3. No abstract available.
HIV in prison in low income countries.
Angora B, Assemien J, Laurent A, Febro V, Coulibaly-Offia M, Masumbuko JM, Kakou RA, Traore VE, Eholie S, Brucker G, Lacoste D, Raguin G.
AIDS. 2011 Jun 1;25(9):1244-6. No abstract available.
The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.
Barnabas RV, Webb EL, Weiss HA, Wasserheit JN.
AIDS. 2011 Aug 24;25(13):1559-73. Review.
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.
Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group.
AIDS. 2011 Jul 31;25(12):1505-13.
Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.
Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ.
AIDS. 2011 Jun 1;25(9):1163-74.
Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
Kerkhoff AD, Wood R, Lawn SD.
AIDS. 2011 Apr 24;25(7):1003-6.
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
Kwara A, Lartey M, Sagoe KW, Court MH.
AIDS. 2011 Jan 28;25(3):388-90.
'Team up against TB': promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy.
Grant AD, Coetzee L, Fielding KL, Lewis JJ, Ntshele S, Luttig MM, Mngadi KT, Muller D, Popane F, Mdluli J, Mngadi N, Sefuthi C, Clark DA, Churchyard G.
AIDS. 2010 Nov;24 Suppl 5:S37-44.
Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening.
Churchyard GJ, Fielding KL, Lewis JJ, Chihota VN, Hanifa Y, Grant AD.
AIDS. 2010 Nov;24 Suppl 5:S19-27.
Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions.
Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M.
AIDS. 2010 Nov;24 Suppl 5:S57-65. No abstract available.
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ.
AIDS. 2010 Nov;24 Suppl 5:S5-13.
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE.
AIDS. 2010 Nov;24 Suppl 5:S49-56.
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD.
AIDS. 2010 Nov;24 Suppl 5:S45-8.
Adverse events with isoniazid preventive therapy: experience from a large trial.
Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ.
AIDS. 2010 Nov;24 Suppl 5:S29-36.
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
Grant AD, Fielding KL, Charalambous S, Chaisson RE, Churchyard GJ.
AIDS. 2010 Nov;24 Suppl 5:S15-8. No abstract available.
Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.
Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE.
AIDS. 2010 Nov;24 Suppl 5:S1-3. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on